Arthritis, Gouty clinical trials
The registry lists 47 studies for Arthritis, Gouty across more than 10 countries. 16 are recruiting or about to start. 34 of them are mainly about Arthritis, Gouty (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.
Get an email when these change. Save the Arthritis, Gouty studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Novartis Pharmaceuticals (6) · Arthrosi Therapeutics (5) · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (3) · Innovent Biologics (Suzhou) Co. Ltd. (2) · Radnor Registry Research, Inc (1) · Shanghai Yueyang Integrated Medicine Hospital (1) · Olatec Therapeutics, Inc. (1) · Haiphong University of Medicine and Pharmacy (1)
What is being tested here
Drugs under test in Arthritis, Gouty studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Dec 2026Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare · Phase 3 · Olatec Therapeutics, Inc.
- Dec 2026Efficacy Anda Safety of Etoricoxib With Betamethasone for the Treatment of Acute Gout Arthritis · Phase 3 · Laboratorios Silanes S.A. de C.V.
- Nov 2026Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients · Arthrosi Therapeutics
- May 2027A Study of Efficacy and Safety of IBI3011 in Subjects With Acute Gouty Arthritis · Innovent Biologics (Suzhou) Co. Ltd.
- Jun 2027Digital Care for Holistic Health in Older Adults With Diabetes and Multimorbidity · Chang Gung University of Science and Technology
- Jun 2027HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness · Haiphong University of Medicine and Pharmacy
- Jul 2027Musculoskeletal Ultrasound for Differentiating Rheumatoid and Gouty Arthritis · Assiut University
- Aug 2027Nurse-Led Telehealth for Gout · University of Aarhus
- Aug 2027A Study of SSGJ-613 in Gout Participants Initiating Urate-Lowering Treatment · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- Aug 2027Purified Cortrophin® Gel Efficacy and Safety Study of 2 Dose Levels in Patients With Acute Gout Flares · Massachusetts General Hospital
Who these studies take
Of the 10 Arthritis, Gouty studies recruiting now, 8 (80%) set no upper age limit and 1 (10%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (10%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 9 (90%) | 9 (90%) |
| 30 | 9 (90%) | 9 (90%) |
| 40 | 9 (90%) | 9 (90%) |
| 50 | 10 (100%) | 10 (100%) |
| 65 | 10 (100%) | 10 (100%) |
| 75 | 10 (100%) | 10 (100%) |
| 85 | 9 (90%) | 9 (90%) |
Across all 47 studies, recruiting or not: 28% stop at 75 or younger and 11% at 65; 6% take children; 0% are for women only and 2% for men only; 13% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 14, 2026.
Started recruiting1
- Pharmacist-Led Treat-to-Target Urate Lowering Therapy in Patients With GoutOct 21, 2026NCT06887452
Studies
Recruiting first, then most recently updated. Showing 47 of 47. search them.
- A Study of Efficacy and Safety of IBI3011 in Subjects With Acute Gouty ArthritisRecruitingNCT07842497Phase 21 country
- Pharmacist-Led Treat-to-Target Urate Lowering Therapy in Patients With GoutRecruitingNCT06887452Not applicable1 country
- A Study to Evaluate the Efficacy,Safety,Tolerability,Pharmacokinetics,and Immunogenicty of Plonmarlimab in Subjects With Acute Gouty ArthritisRecruitingNCT07453004Phase 21 country
- Clinical Study of HRS-2129 for Acute Gouty ArthritisRecruitingNCT07706777Phase 21 country
- Mass Spectrometry-based Immune Profiling in Autoimmune DiseasesEnrolling by invitationNCT071882851 country
- Digital Care for Holistic Health in Older Adults With Diabetes and MultimorbidityRecruitingNCT07310849Not applicable1 country
- A Study of SSGJ-613 in Gout Participants Initiating Urate-Lowering TreatmentNot yet recruitingNCT07708181Phase 2
- Musculoskeletal Ultrasound for Differentiating Rheumatoid and Gouty ArthritisNot yet recruitingNCT07657156
- Study of Dapansutrile Tablets in Subjects With an Acute Gout FlareRecruitingNCT05658575Phase 2/35 countries
- HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-EffectivenessNot yet recruitingNCT07369622Phase 4
- Purified Cortrophin® Gel Efficacy and Safety Study of 2 Dose Levels in Patients With Acute Gout FlaresRecruitingNCT07346079Phase 41 country
- An Exploratory Clinical Study on the Protective Effect of Cycling on the Ankle Joint in GoutNot yet recruitingNCT07312396Not applicable
- Nurse-Led Telehealth for GoutRecruitingNCT06971146Not applicable1 country
- Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and EfficacyRecruitingNCT071500001 country
- Efficacy Anda Safety of Etoricoxib With Betamethasone for the Treatment of Acute Gout ArthritisRecruitingNCT06863701Phase 31 country
- The MAD Study of SSGJ-613 in Healthy SubjectsNot yet recruitingNCT05966701Phase 11 country
- Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)CompletedNCT06439602Phase 35 countries
- Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)CompletedNCT06846515Phase 31 country
- Role of ASICs in Human Inflammatory PainCompletedNCT018678401 country
- Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed PatientsActive, not recruitingNCT07116746Phase 21 country
- A Study to Evaluate Efficacy and Safety of Qingzhu Granules in the Treatment of Acute Gouty ArthritisCompletedNCT06068478Phase 31 country
- A Bioequivalence Study of Two Different Dosage Form of GenakumabCompletedNCT06451848Phase 11 country
- Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous GoutCompletedNCT05253833Phase 23 countries
- A Study of SSGJ-613 in Gout Subjects Initiating Urate-Lowering Treatment.Active, not recruitingNCT06270225Phase 21 country
- The Impact of Metformin on the Outcome of Gouty Arthritis in a Cohort of Egyptian Gouty Patients.CompletedNCT05332795Not applicable1 country
- A Study to Investigate the Pharmacokinetic/Pharmacodynamic Characteristics of IBI128(A New Xanthine Oxidase Inhibitor)CompletedNCT06277752Phase 11 country
- Real-life Study of the Characteristics of Patients Treated With Ilaris® (Canakinumab) for Gouty Arthritis in FranceCompletedNCT059649461 country
- Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout PatientsCompletedNCT05119686Phase 23 countries
- NLRP3 Inflammasome Activation Among Patients During Acute Gout FlaresStatus unknownNCT057442971 country
- Evaluation and Characterisation of Microplastics and Nanoplastics in Joint Synovial LiquidStatus unknownNCT05678049
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Evaluation of RPH-104 Administered at Different Doses to Patients With Acute Gout AttackTerminatedNCT04067492Phase 21 country
- β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)CompletedNCT01470989Phase 39 countries
- Long Term Study of Canakinumab (ACZ885) in Patients With GoutCompletedNCT00927810Phase 218 countries
- Sonographic Signs of Gouty Arthritis in a Cohort of Egyptian Patients: a Cross Sectional Multicenter StudyCompletedNCT047340931 country
- The Relationship Between Cold Water Immersion and the Progression in Gout ArthritisCompletedNCT04587544Not applicable1 country
- Celebrex In Acute Gouty Arthritis StudyCompletedNCT00549549Phase 312 countries
- Oral Huzhang Granules for Acute Gouty ArthritisStatus unknownNCT04462666Phase 2
- A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)CompletedNCT00819585Phase 218 countries
- A Proof-of-Concept Study of AC-201 to Prevent Gout FlaresCompletedNCT01712204Phase 21 country
- Safety & Efficacy of Canakinumab (ACZ885) in Patients With Frequent Flares for Whom Nonsterodial Anti-Inflammatory Drug (NSAIDs) and/ or Colchicine Are Contraindicated, Not Tolerated or IneffectiveTerminatedNCT01362608Phase 34 countries
- Canakinumab in the Treatment of Gouty Arthritis Flare(s) and Prevention of New Flares in Patients With Chronic Kidney DiseaseWithdrawnNCT01593527Phase 3
- The Clinical Study on Treating Acute Gouty Arthritis Using Both Internal and External Therapy of Tonifying Spleen and Descending TurbidStatus unknownNCT02545777Phase 21 country
- The Influence of Antiphospholipid Antibodies on the Relationship Between Hyperurecemia, Gout and Metabolic SyndromeStatus unknownNCT018185051 country
- AMPED Outcomes Registry of Post-ED Pain ManagementCompletedNCT016262351 country
- Italian Observational Study Assessing the Impact of Gout on Patients Disability and Quality of LifeCompletedNCT015492101 country
- Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute GoutCompletedNCT00663169Phase 23 countries
- Re-exposure Study of Pegloticase Intravenous (i.v.) in Symptomatic Gout PatientsCompletedNCT00675103Phase 31 country